| Primary |
| Acute Lymphocytic Leukaemia |
70.5% |
| T-cell Lymphoma Stage Iv |
9.5% |
| Product Used For Unknown Indication |
9.2% |
| Chemotherapy |
2.3% |
| B Precursor Type Acute Leukaemia |
2.2% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
0.9% |
| Acute Myeloid Leukaemia |
0.6% |
| B-cell Type Acute Leukaemia |
0.6% |
| T-cell Lymphoma |
0.6% |
| T-cell Type Acute Leukaemia |
0.6% |
| Prophylaxis |
0.5% |
| Drug Use For Unknown Indication |
0.5% |
| Leukaemia |
0.3% |
| Lymphoma |
0.3% |
| Mediastinal Mass |
0.3% |
| Neoplasm Malignant |
0.3% |
| Acute Leukaemia |
0.2% |
| Acute Lymphocytic Leukaemia Recurrent |
0.2% |
| Burkitt's Lymphoma |
0.2% |
| Chronic Myeloid Leukaemia |
0.2% |
|
| Hypersensitivity |
34.5% |
| Infection |
11.0% |
| Embolism |
8.9% |
| Neutropenia |
6.8% |
| Osteonecrosis |
6.4% |
| Thrombosis |
5.9% |
| Sepsis |
5.5% |
| Embolism Venous |
2.1% |
| Pancreatitis |
2.1% |
| Toxicity To Various Agents |
2.1% |
| Convulsion |
1.9% |
| Drug Toxicity |
1.9% |
| Hepatotoxicity |
1.9% |
| Superior Sagittal Sinus Thrombosis |
1.5% |
| Vomiting |
1.5% |
| Death |
1.3% |
| Neurotoxicity |
1.3% |
| Pancreatitis Acute |
1.3% |
| Pyrexia |
1.1% |
| Fungal Infection |
0.9% |
|
| Secondary |
| Acute Lymphocytic Leukaemia |
73.1% |
| Product Used For Unknown Indication |
5.9% |
| B Precursor Type Acute Leukaemia |
4.4% |
| Antifungal Prophylaxis |
1.6% |
| Prophylaxis |
1.5% |
| Infection Prophylaxis |
1.4% |
| Lymphocytic Leukaemia |
1.4% |
| Drug Use For Unknown Indication |
1.3% |
| Extranodal Nk/t-cell Lymphoma, Nasal Type |
1.2% |
| Chemotherapy |
1.1% |
| Lymphoma |
0.9% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
0.9% |
| Leukaemia |
0.9% |
| Acute Lymphocytic Leukaemia Recurrent |
0.8% |
| Ataxia Telangiectasia |
0.7% |
| Diffuse Large B-cell Lymphoma |
0.7% |
| Neoplasm Malignant |
0.6% |
| Acute Myeloid Leukaemia |
0.5% |
| Anaplastic Large Cell Lymphoma T- And Null-cell Types |
0.5% |
| Antibiotic Prophylaxis |
0.4% |
|
| White Blood Cell Count Decreased |
10.3% |
| Leukoencephalopathy |
9.1% |
| Off Label Use |
9.1% |
| Vomiting |
7.3% |
| Encephalopathy |
5.5% |
| Neuropathy Peripheral |
5.5% |
| Cerebral Infarction |
4.8% |
| Pneumonia |
4.8% |
| Spinal Disorder |
4.8% |
| Thrombocytopenia |
4.8% |
| Septic Shock |
4.2% |
| Bone Marrow Failure |
3.6% |
| Hypothyroidism |
3.6% |
| Posterior Reversible Encephalopathy Syndrome |
3.6% |
| Thymus Enlargement |
3.6% |
| Candidiasis |
3.0% |
| Hyperglycaemia |
3.0% |
| Neurotoxicity |
3.0% |
| Oedema Peripheral |
3.0% |
| Reversible Posterior Leukoencephalopathy Syndrome |
3.0% |
|
| Concomitant |
| Acute Lymphocytic Leukaemia |
38.5% |
| Prophylaxis |
10.2% |
| Neoplasm Malignant |
9.7% |
| Chemotherapy |
6.0% |
| Drug Use For Unknown Indication |
4.1% |
| Acute Lymphocytic Leukaemia Recurrent |
3.3% |
| Acute Myeloid Leukaemia |
3.0% |
| Febrile Neutropenia |
3.0% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
2.9% |
| Stem Cell Transplant |
2.7% |
| Product Used For Unknown Indication |
2.3% |
| Supplementation Therapy |
2.2% |
| Prophylaxis Against Graft Versus Host Disease |
2.1% |
| Bone Marrow Conditioning Regimen |
1.9% |
| Fungal Infection |
1.8% |
| Non-hodgkin's Lymphoma |
1.4% |
| Extranodal Nk/t-cell Lymphoma, Nasal Type |
1.2% |
| Pancreatitis |
1.2% |
| T-cell Lymphoma |
1.2% |
| Aspergillosis |
1.1% |
|
| Neuropathy Peripheral |
17.9% |
| Hy's Law Case |
9.0% |
| Renal Failure |
7.7% |
| White Blood Cell Count Decreased |
6.4% |
| Nervous System Disorder |
5.1% |
| Vomiting |
5.1% |
| Acute Graft Versus Host Disease |
3.8% |
| Ileus Paralytic |
3.8% |
| Leukaemia Recurrent |
3.8% |
| Mucosal Inflammation |
3.8% |
| Neurotoxicity |
3.8% |
| Pancytopenia |
3.8% |
| Pyrexia |
3.8% |
| Sepsis |
3.8% |
| Vith Nerve Paralysis |
3.8% |
| Weight Increased |
3.8% |
| Acute Lymphocytic Leukaemia |
2.6% |
| Aspartate Aminotransferase Increased |
2.6% |
| Drug Effect Decreased |
2.6% |
| Drug Interaction |
2.6% |
|
